← Sage — Eye · Sage hub

Sage — Glaucoma

Sage

Glaucoma: energy-dependent axonal transport at the lamina cribrosa

In primary open-angle glaucoma, the RGC soma resides in the ganglion-cell layer, yet critical mechanical stress (and, in this model, energetic stress) occurs along its long axon as it bundles at the optic nerve head and passes through the pores of the lamina cribrosa. Axonal transport — moving mitochondria, neurotrophic factors, and cargoes anterogradely and retrogradely — is ATP-intensive (kinesin/dynein). When level 0–1 mitochondrial capacity is marginal, transport may become inefficient. At the lamina cribrosa, axons encounter a physical bottleneck where IOP elevations can produce focal compression, kinking, or “crimp in the hose,” impeding flow and, in this model, increasing transport energy cost. Localized strain superimposed, in this model, on already compromised ATP production triggers soma-level stress signaling and eventual apoptosis — even though the nucleus is far upstream in the retina.

On this hypothesis, elevated IOP may in part be a downstream consequence of trabecular-meshwork mitochondrial insufficiency (impaired ECM turnover and contractility raising outflow resistance), yet it acts as a potent mechanical amplifier at the cribriform bottleneck. IOP lowering (drops, lasers, MIGS, filtration surgery) is the only treatment proven to slow glaucoma progression; in this model, it works by reducing additional strain on an energetically fragile axonal-transport system, buying margin for cells with limited reserve. It could also account for ocular hypertension without glaucoma — eyes with high IOP but sufficient mitochondrial and transport capacity to tolerate load without crossing apoptotic threshold. Conversely, normal-tension glaucoma or progression despite “target” IOP may reflect, in part, a level 0–1 deficit (impaired vascular autoregulation is one other proposed reason): axons may not sustain transport even at normal pressures when the mitochondrial engines are inadequate. Pressure still matters in these eyes, though: lowering IOP by 30% slowed progression in normal-tension glaucoma, and treatment slowed progression in normal-tension eyes in EMGT. A focus on pressure, the only proven modifiable risk factor, may miss that the lamina cribrosa is not merely a passive mechanical weak point but, in this model, an energetic choke point whose tolerance depends on RGC axonal bioenergetics. Neuroprotection trials such as those of memantine have failed, perhaps because they do not restore ATP supply to the transport pump itself; an early trial of an NAD⁺ precursor, which targets energy metabolism, improved inner retinal function.

Good Doctor layer language: “Primary open-angle glaucoma” points at a pressure and a nerve — sometimes the actionable layer this week. “RGCs and trabecular meshwork running on insufficient mitochondrial headroom in a person whose systemic prior is also missed” points at a different layer that explains why pressure-lowering alone so often fails to stop the field. Both names can be true. Only one of them tells you what else to do. On this hypothesis, systemic hypertension and ocular hypertension look less like coincidences and more like cousins: remodeling to keep flow through underpowered tissue, nitric oxide, ECM stiffening, company with insulin resistance.

Lowering eye pressure is still the only treatment proven to slow glaucoma. Nothing here replaces drops, laser, or surgery, and any change to glaucoma or blood-pressure medicines belongs with your physician.

Glaucoma: Three Compartments, One Matching Failure

Glaucoma is not one disease sitting in one tissue. It is retinal ganglion cell axonal failure at a pressure, perfusion, and strain interface. NO is involved at all three sites that matter---trabecular meshwork and Schlemm's canal, lamina cribrosa, and the ganglion cell axon---and the dual face of the gas is sharper here than in the penis.

Trabecular meshwork and Schlemm's canal are the arteriole of aqueous. Raise intraocular pressure and the meshwork stretches, Schlemm's canal narrows, and shear on canal endothelium rises to levels comparable to large arteries. Canal endothelial cells then make NO in response to shear. The gas diffuses bidirectionally: trabecular cells relax, the inner wall of the canal becomes more permeable, distal collector channels dilate. Outflow facility rises. Pressure falls. Shear falls. A barostat. In mice, eNOS overexpression lowers pressure; NOS3 variants are linked to high-tension glaucoma only in some subgroups. Conventional outflow tissue from primary open-angle glaucoma often shows less NO tone. Latanoprostene bunod is a marketed drop built on this idea: latanoprost opens uveoscleral outflow; in nonclinical studies, the nitric oxide moiety opens conventional outflow through the same cGMP–PKG relaxation used in vessels.

Acute: stretch and shear → NO → lower resistance to aqueous. Good compensation, one-for-one with vascular Act I.

Chronic energy and redox failure in canal and meshwork endothelium: the barostat rusts. Outflow resistance stays high. The intraocular pressure set point drifts up. That is the anterior scar.

The lamina cribrosa is the mechanical and vascular bottleneck. Ganglion cell axons leave through a perforated collagen plate, the weakest point in the scleral wall. Translaminar pressure---intraocular pressure minus retrolaminar cerebrospinal fluid pressure---strains the plate, kinks axons, stops axoplasmic flow, and can collapse capillaries in the laminar beams. Perfusion pressure at the optic nerve head is roughly mean arterial pressure minus intraocular pressure. NO from eNOS in nerve-head vessels is part of the autoregulation that should keep flow when pressure rises or arterial pressure dips, including the nocturnal dips that also appear in non-arteritic anterior ischemic optic neuropathy. Failed autoregulation may help explain why some people get glaucoma at "normal" pressure, and why a stiff, high-systolic, low-diastolic circulation may not be safe for the disc. Mechanical strain plus poor matching is the chronic lock. In this reading, NO does not soften the lamina the way it relaxes meshwork; it mainly defends the blood supply through it. Excess NOS-1 and NOS-2 in glaucomatous nerve-head astrocytes is the other face: possibly too much NO and peroxynitrite next to axons.

Retinal ganglion cells are the load. The intraocular axon is unmyelinated and metabolically expensive. Mitochondria must traffic through the lamina. In this model, pressure strain and poor nerve-head perfusion produce a local ATP crisis in the axon: transport fails, the soma loses neurotrophic return, the cell dies. The field defect is not a random scotoma: it follows the nerve-fiber bundles, and in this model it maps which bundles lived longest in the worst strain and perfusion. That is as close as clinical ophthalmology gets to a chronic ATP-deficit cascade written on a visual field. Physiologic NO can help by keeping pressure down and nerve-head flow up. Pathologic inducible NO at the head can kill the same axons. Higher dietary nitrate associating with lower open-angle glaucoma risk---especially paracentral field loss, the subtype tied to vascular dysregulation---fits a perfusion and matching story more than a pure pressure story.

On this hypothesis, hypertension and glaucoma may share a structure that the single-location story misses: not one ATP deficit in one cell type, but multiple simultaneous deficits from the normal homeostatic operating procedure (barostat, autoregulation, and high-cost axon, or endothelium, kidney, and resistance artery) failing together because they share chemistry and a chronic operating mode. In population studies, high blood pressure is modestly linked with open-angle glaucoma, and so are low pressure and deep night-time dips. Animal studies support the cellular part of that picture; a shared cause in people has not been shown.

What Nitric Oxide Does in Glaucoma

Anterior segment: pressure- and shear-dependent eNOS, then cGMP, then lower outflow resistance, then lower intraocular pressure. This is the vascular analogy, almost one-for-one.

Optic nerve head vessels: eNOS and nitrergic nerves supporting autoregulation of flow against intraocular pressure and nocturnal arterial dips.

Ganglion cells and astrocytes: constitutive low-flux NO is compatible with signaling and blood flow; induced high-flux NO is a candidate axon toxin.

Therapy that follows: restore conventional outflow with an NO donor (a prescription eye drop such as latanoprostene bunod, chosen with your eye doctor) when the barostat is the constraint; do not assume more NO at the lamina is better. The dual face is the same dual face as in plaque biology. Coupled, shear-timed, nanomolar NO is matching. Uncoupled or inducible high-output NO is a scar-making oxidant.

Corollaries of Hypertension and Glaucoma

Endothelial Parallels, Nitric Oxide, Macrophages, and Extracellular Matrix — A Hypothesis of Shared Mitochondrial Metabolic Causation

Abstract

Hypertension and primary open-angle glaucoma exhibit striking cellular and tissue-level parallels: endothelial-like cells regulating tone and permeability, central reliance on nitric oxide (NO) signaling, macrophage-like immune participation, and pathology centered on extracellular matrix (ECM) turnover and stiffening. Both conditions share risk factors (age, metabolic syndrome, insulin resistance) and share or borrow overlapping pharmacologic classes. This essay advances the hypothesis that mitochondrial bioenergetic dysfunction and redox imbalance constitute the common upstream metabolic driver. Impaired ATP production, excessive mitochondrial reactive oxygen species (mtROS), and consequent oxidative stress uncouple eNOS, impair energy-dependent processes, activate pro-inflammatory phenotypes, and dysregulate ECM remodeling in both the vascular tree and the conventional aqueous outflow pathway. The framework integrates mechanistic evidence and suggests therapeutic reorientation toward mitochondrial optimization alongside conventional symptom control.

Introduction

Hypertension and primary open-angle glaucoma (POAG, including normal-tension variants) are age-associated chronic conditions imposing enormous burdens on cardiovascular and visual health. Both feature striking cellular and tissue-level parallels: endothelial-like or smooth muscle-like cells that regulate tone and permeability; central reliance on nitric oxide (NO) signaling for homeostasis; involvement of macrophage-like or microglia-like immune cells in inflammation and remodeling; and pathology centered on extracellular matrix (ECM) turnover and stiffening. Clinically, they share risk factors (age, metabolic syndrome features including insulin resistance and obesity, diabetes) and share or borrow overlapping pharmacologic classes (beta-blockers in both; rho-kinase and NO pathways studied in both). Systemic hypertension has a modest association with open-angle glaucoma. The link is U-shaped: low blood pressure, including low pressure driving blood into the eye and blood-pressure dips at night, is also linked to higher risk. The connection may run through eye pressure (IOP) or blood flow to the optic nerve. It is an association, not proven cause.

These corollaries raise a deeper question: Is there a common root metabolic causation — a shared upstream driver — rather than merely convergent downstream phenotypes? The hypothesis advanced here is that mitochondrial bioenergetic dysfunction and redox imbalance constitute that root driver. Impaired mitochondrial ATP production, excessive mitochondrial reactive oxygen species (mtROS), disrupted fission/fusion/mitophagy, and consequent oxidative stress uncouple endothelial nitric oxide synthase (eNOS), impair energy-dependent cellular processes, activate pro-inflammatory immune phenotypes, and dysregulate ECM remodeling in both the vascular tree (hypertension) and the conventional aqueous outflow pathway (glaucoma). This framework integrates mechanistic evidence across disciplines and aligns with broader metabolic hypotheses of disease that prioritize cellular energy failure over isolated organ-system explanations.

Endothelial-like Cells and the NO Feedback Loop: Vascular and Ocular Outflow Parallels

In the systemic vasculature, endothelial cells sense shear stress and stretch, activating eNOS to produce NO. NO diffuses to vascular smooth muscle, activating soluble guanylyl cyclase (sGC), raising cGMP, and promoting relaxation — lowering peripheral resistance and blood pressure. Endothelial dysfunction (reduced NO bioavailability) is a hallmark of hypertension, driving vasoconstriction, vascular remodeling, and stiffness.

A remarkably analogous system operates in the eye’s conventional outflow pathway. Trabecular meshwork (TM) cells exhibit smooth muscle-like contractile properties and express eNOS; Schlemm’s canal (SC) is lined by specialized endothelium. These tissues form a mechanosensitive feedback loop that maintains IOP homeostasis. When IOP rises, the outflow tissues distend and the SC lumen narrows, increasing endothelial shear stress and cellular stretch on SC cells. In response, SC endothelium upregulates eNOS-derived NO, which relaxes adjacent TM cells (reducing their contractile tone and thereby decreasing resistance) and increases permeability of the SC inner wall. The net effect augments aqueous humor drainage, lowers IOP, and reduces the original biomechanical stimulus — a negative-feedback loop, as proposed in one comprehensive model, that closely parallels vascular autoregulation.

Dysregulation of this eNOS/NO axis is proposed to produce ocular hypertension and contribute to POAG pathogenesis, much as eNOS uncoupling contributes to systemic hypertension. Genetic support is suggestive: in a large US study, variants in NOS3 (the gene for eNOS) changed how strongly high blood pressure and smoking were tied to glaucoma, and some of the same variants are associated with hypertension in a meta-analysis. TRPV4 channels in TM cells, mechanosensitive calcium channels that activate eNOS, are impaired in glaucomatous human TM cells; their pharmacologic activation improves outflow facility and lowers IOP in mice, while TM-specific knockout elevates IOP. Caveolin-1 is a key regulator of eNOS. Common gene variants near CAV1 and CAV2 are associated with open-angle glaucoma in people, and mice lacking caveolin-1 have high eye pressure from poor drainage, so caveolin-1 may link vascular health and glaucoma risk.

The NO-donating prostaglandin latanoprostene bunod (Vyzulta) lowers IOP in clinical use; its NO arm is thought to relax the trabecular meshwork, acting in part through this pathway and mirroring the vessel-relaxing effects of NO-boosting strategies in hypertension. Nipradilol, a beta-blocker eye drop with an NO-donating group (approved in Japan), shows that the drug classes overlap, though its label credits its pressure lowering mainly to beta- and alpha-1-blockade. These parallels may not be coincidental; they may reflect conserved mechanotransduction and NO-mediated relaxation modules repurposed for IOP versus blood-pressure control.

Macrophage-like Cells and Innate Immune Activation

Both conditions feature prominent innate immune participation. In glaucoma models, elevated IOP is accompanied by retinal and optic nerve head microglial activation and monocyte infiltration. Microglia are thought to shift toward pro-inflammatory (M1-like) phenotypes early, releasing cytokines (IL-1β, TNF-α) via NLRP3 inflammasome activation and contributing to retinal ganglion cell (RGC) apoptosis and axonal loss. Later or context-dependent M2 polarization can be neuroprotective, but chronic imbalance favors neurodegeneration. Macrophages also participate in SC development and, in disease, may influence distal outflow remodeling.

In hypertension and its vascular complications (especially atherosclerosis), macrophages infiltrate the vessel wall, become foam cells, amplify oxidative stress and inflammation, and drive ECM deposition and plaque formation. Perivascular macrophages and vascular smooth muscle phenotypic switching further entrench remodeling.

Shared upstream signals include oxidative stress and energy deficit. Mitochondrial ROS and impaired NAD+ metabolism favor M1 polarization and inflammasome activation while impairing resolution. In both tissues, chronic low-grade inflammation sustains the vicious cycles of endothelial dysfunction and ECM pathology. Calming microglia (with minocycline) or blocking monocyte entry into the optic nerve head has been neuroprotective in mouse glaucoma models, though in one mouse study depleting microglia worsened optic nerve damage; analogous anti-inflammatory or metabolic reprogramming strategies show promise in vascular models.

Extracellular Matrix Remodeling: Stiffness and Fibrosis as Common Endpoints

ECM pathology is central to both. In the TM/juxtacanalicular region, glaucomatous eyes show excess collagen, fibronectin and other matrix, altered MMP/TIMP balance and impaired turnover; donor meshwork from glaucoma eyes is stiffer, and in mice a fibronectin variant (EDA) drives matrix buildup and glaucoma-like damage. TGF-β2 (elevated in glaucomatous aqueous humor), connective tissue growth factor (CTGF), integrin signaling (particularly αvβ3), and Rho/ROCK pathway activation are thought to drive a fibrosis-like state. Mechanical stretch on TM cells and glucocorticoids (steroid-induced glaucoma) further upregulate these profibrotic programs, stiffening the meshwork and obstructing outflow.

In hypertension, large and resistance arteries undergo ECM remodeling: elastic fiber fragmentation, excessive collagen deposition (types I and III), proteoglycan changes, and loss of compliance — producing arterial stiffness that elevates systolic pressure and perpetuates end-organ damage. TGF-β, CTGF, integrins, ROCK, and mechanosensing via focal adhesions similarly mediate vascular smooth muscle phenotypic switching to myofibroblast-like states and matrix accumulation.

Mechanobiological feedback loops are conserved. Increased stiffness or altered strain amplifies profibrotic signaling (integrin clustering → RhoA → ROCK → myosin light chain phosphorylation and further matrix production). In both locales, the ECM is not passive scaffolding but an active participant that feeds back on cellular phenotype. Rho-kinase inhibitors (netarsudil, Rhopressa, for glaucoma, which acts on the trabecular meshwork, lowers episcleral venous pressure and in lab work blocks TGF-β2-driven scarring changes in meshwork cells; fasudil and analogs studied in hypertension and vascular remodeling) address this downstream contractility/ECM axis in both conditions, providing another pharmacologic corollary.

The Unifying Metabolic Root: Mitochondrial Dysfunction as Upstream Driver

On this hypothesis, the endothelial-NO, immune, and ECM parallels converge most parsimoniously at the mitochondrion. TM cells grown from glaucoma patients’ tissue show lower ATP, reduced mitochondrial membrane potential and excess ROS; their meshwork shows more mitochondrial DNA damage; and in a mouse glaucoma model the meshwork mitochondria are swollen with fewer cristae. On this hypothesis, elevated IOP itself may induce mitochondrial oxidative stress in TM cells, which may create a self-amplifying cycle of bioenergetic failure, cell detachment/apoptosis, and pathological ECM remodeling. In Lmx1b mutant mice, mitochondrial changes in one meshwork cell subtype (TM3) appear around the onset of the pressure rise and may help drive it; in lab-grown human meshwork cells, a disease-causing myocilin mutation impairs mitochondria. Nicotinamide (vitamin B3, an NAD+ precursor) protected Lmx1b mutant mice from IOP rise, possibly by improving mitochondrial resilience. In people, nicotinamide is being tested in glaucoma trials but is not a proven treatment and does not replace prescribed drops. Mitochondrial transplantation into the front chamber of the eye lowered IOP in one mouse model of ocular hypertension; it is experimental and has not been tried in people.

Endothelial cells are equally vulnerable. Reactive oxygen species (in one mouse model, from NADPH oxidase; on this hypothesis, also from mitochondria) oxidize tetrahydrobiopterin (BH4), uncoupling eNOS so that it produces superoxide instead of NO — a central mechanism of endothelial dysfunction in hypertension. In pulmonary hypertension models, eNOS uncoupling initiates ER stress that further impairs mitochondria; scavenging mtROS or recoupling eNOS attenuates vascular remodeling and pressure elevation. In mouse models, hypertension features downregulated SIRT3, inactivated SOD2, and mitochondrial oxidative stress that promotes vascular fibrosis and stiffness. Insulin resistance and metabolic syndrome — shared risk amplifiers for both hypertension and glaucoma — may originate in and exacerbate mitochondrial dysfunction across tissues.

On this hypothesis, a single upstream insult — mitochondrial energy deficit plus redox imbalance — would explain the downstream corollaries:

  • NO pathway failure: mtROS → BH4 oxidation → eNOS uncoupling → reduced NO bioavailability in SC/TM (↑ outflow resistance, ↑ IOP) and in vessels (↑ tone, remodeling).
  • Immune activation: Energy failure and mtROS favor pro-inflammatory macrophage/microglial polarization and inflammasome activity.
  • ECM dysregulation: ATP depletion and ROS impair balanced MMP activity and resolution while promoting TGF-β/CTGF/integrin/ROCK-driven fibrosis and stiffness in both TM and vascular walls.
  • Mechanosensing collapse: Mitochondria support calcium handling and ATP-dependent processes required for TRPV4, PIEZO, and integrin signaling; their failure blunts adaptive responses to shear/stretch in SC endothelium and TM cells, just as in vascular endothelium.

Steroid-induced glaucoma may exemplify the metabolic link: in one study in mice and cultured human TM cells, stress-level steroid hormones (corticosterone, cortisol) drove mitochondrial fission through MAOA-MIEF1-DRP1 signaling, along with oxidative stress and scarring-type changes. Whether steroid drops or pills act the same way has not been shown. In one study, Black patients with severe glaucoma had higher oxidative DNA damage (8-OHdG) in the fluid inside the eye than White patients, and lab-grown meshwork cells from healthy Black donors had more mitochondria and made more ROS under stress; the authors suggest this may contribute to racial disparities in glaucoma.

Cardiometabolic syndrome (obesity, insulin resistance, hypertension, dyslipidemia) may amplify risk for both conditions, on this hypothesis through these mitochondrial mechanisms, sympathetic overdrive (raising IOP and vascular tone), and shared oxidative/inflammatory milieus. In a nationwide Korean study of 32,220 glaucoma suspects, those with diabetes, high blood pressure, high cholesterol or coronary heart disease were modestly more likely to develop open-angle glaucoma over a 6-year follow-up (hazard ratios 1.124 to 1.354), consistent with a systemic metabolic substrate.

Therapeutic Implications: From Symptomatic Control to Root Metabolic Stewardship

Current management remains largely symptomatic and compartmentalized: IOP-lowering drops or surgery for glaucoma; antihypertensives for blood pressure. For glaucoma, lowering eye pressure with drops, laser or surgery is the only treatment proven to slow vision loss; nothing proposed here replaces it, and any change to prescribed treatment belongs with your doctor. These interventions are valuable yet address downstream manifestations. Rho-kinase inhibitors relax contractile tone and may modestly improve ECM dynamics in both systems but do not restore mitochondrial health. NO-donating agents augment the deficient signal without correcting the oxidative uncoupling that, on this hypothesis, caused it.

A metabolic hypothesis directs attention upstream. Interventions that improve mitochondrial biogenesis, quality control (mitophagy), NAD+ pools, and redox balance — ketogenic or time-restricted feeding patterns emphasizing animal fats/proteins and fermented matrix carbohydrates, strategic fasting, dynamic resistance training, circadian alignment of light/sleep/meals, and targeted cofactors (PQQ, NR/NMN, CoQ10, methylene blue in appropriate contexts) — may address the shared driver. Such approaches align with frugal philosophy: low-cost, ancestral-patterned inputs that leverage evolved bioenergetic resilience alongside, not instead of, proven drug therapy.

Methylene blue: Not a protocol for self-dosing and not a consumer dose schedule. This essay does not diagnose, treat, or prescribe. A licensed clinician who knows the person sets any use — or none. G6PD deficiency is a contraindication. Dangerous with many serotonergic medications (serotonin-syndrome risk). Use only pharmaceutical-grade (USP) material — never aquarium or industrial dye. High exposures can invert the redox effect.

Animal evidence is suggestive: an NAD+ precursor protected against IOP rise in a genetic mouse glaucoma model; mitochondrial transplantation offers an experimental proof-of-concept in mice. In hypertension models, preserving mitochondrial antioxidant defenses (SIRT3/SOD2) or recoupling eNOS attenuates remodeling. Integrated cardiometabolic-ocular care — addressing insulin sensitivity, oxidative stress, and mitochondrial support alongside conventional metrics — may add to what IOP or BP targets alone achieve; that is a testable prediction, not a result.

Testable predictions follow: glaucoma and hypertensive patients should show convergent biomarkers of mitochondrial dysfunction (reduced NAD+/NADH ratios, elevated circulating or local 8-OHdG or mtDNA damage, impaired endothelial or TM bioenergetics); mitochondrial-targeted interventions should improve both vascular compliance and outflow facility beyond what BP/IOP lowering alone achieves; and metabolic syndrome severity should correlate with mitochondrial metrics in both tissues.

Conclusion

Hypertension and glaucoma exhibit deep corollaries at the levels of endothelial-like regulation, NO homeostasis, macrophage participation, and ECM pathology. On this hypothesis, these are not superficial analogies but reflections of conserved cellular modules. The unifying explanation proposed here is a root metabolic causation rooted in mitochondrial energy failure and oxidative stress — uncoupling eNOS, collapsing adaptive mechanosensing and contractility, skewing immune phenotypes toward chronic inflammation, and locking tissues into profibrotic ECM states. This hypothesis integrates clinical epidemiology, cell biology, and emerging interventional data while offering a coherent therapeutic reorientation: toward restoration of cellular bioenergetic integrity, alongside, not instead of, proven drug therapy.

Such a lens does not diminish the value of existing IOP- or BP-lowering therapies but contextualizes them within a larger metabolic architecture. It invites cross-disciplinary investigation — ophthalmologists, cardiologists, and metabolic researchers examining shared mitochondrial biomarkers and interventions — and aligns with a broader program of frugal, first-principles stewardship of human health. The eye and the vasculature, in their parallel vulnerabilities, may be revealing a more fundamental truth about the cellular origins of age-related disease: when mitochondria falter, multiple systems pay the price.

This essay is offered as a hypothesis-generating synthesis, open to refinement by new data on mitochondrial dynamics in human TM and vascular tissues, longitudinal biomarker studies, and rigorous trials of metabolic optimization protocols in patients with comorbid hypertension and glaucoma. The parallels are consistent enough, and the mitochondrial evidence in models convergent enough, to deserve testing in people.

A working hypothesis, open to correction and revised as new evidence arrives. Last revised November 1, 2026.

References

Glaucoma: energy-dependent axonal transport at the lamina cribrosa

  1. Quigley HA, Addicks EM, Green WR, et al., 1981. Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Archives of Ophthalmology 99(4):635-649. doi:10.1001/archopht.1981.03930010635009
  2. Williams PA, Harder JM, Foxworth NE, et al., 2017. Vitamin B(3) modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science 355(6326):756-760. doi:10.1126/science.aal0092
  3. Quigley HA, Addicks EM, 1980. Chronic experimental glaucoma in primates. II. Effect of extended intraocular pressure elevation on optic nerve head and axonal transport. Investigative Ophthalmology & Visual Science 19(2):137-152. doi:
  4. He Y, Leung KW, Zhang YH, et al., 2008. Mitochondrial complex I defect induces ROS release and degeneration in trabecular meshwork cells of POAG patients: protection by antioxidants. Investigative Ophthalmology & Visual Science 49(4):1447-1458. doi:10.1167/iovs.07-1361
  5. Abu-Amero KK, Morales J, Bosley TM, 2006. Mitochondrial abnormalities in patients with primary open-angle glaucoma. Investigative Ophthalmology & Visual Science 47(6):2533-2541. doi:10.1167/iovs.05-1639
  6. Heijl A, Leske MC, Bengtsson B, et al., 2002. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of Ophthalmology 120(10):1268-1279. doi:10.1001/archopht.120.10.1268
  7. Kass MA, Heuer DK, Higginbotham EJ, et al., 2002. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of Ophthalmology 120(6):701-713. doi:10.1001/archopht.120.6.701
  8. Collaborative Normal-Tension Glaucoma Study Group, 1998. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. American Journal of Ophthalmology 126(4):487-497. doi:10.1016/s0002-9394(98)00223-2
  9. Weinreb RN, Liebmann JM, Cioffi GA, et al., 2018. Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies. Ophthalmology 125(12):1874-1885. doi:10.1016/j.ophtha.2018.06.017
  10. Hui F, Tang J, Williams PA, et al., 2020. Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: A crossover randomized clinical trial. Clinical & Experimental Ophthalmology 48(7):903-914. doi:10.1111/ceo.13818

Corollaries of Hypertension and Glaucoma

  1. Cui YK, Pan L, Lam T, et al., 2022. Mechanistic links between systemic hypertension and open angle glaucoma. Clinical and Experimental Optometry 105(4):362-371. doi:10.1080/08164622.2021.1964332
  2. Zhao D, Cho J, Kim MH, et al., 2014. The association of blood pressure and primary open-angle glaucoma: a meta-analysis. American Journal of Ophthalmology 158(3):615-627.e9. doi:10.1016/j.ajo.2014.05.029
  3. Reina-Torres E, De Ieso ML, Pasquale LR, et al., 2021. The vital role for nitric oxide in intraocular pressure homeostasis. Progress in Retinal and Eye Research 83:100922. doi:10.1016/j.preteyeres.2020.100922
  4. Stamer WD, Lei Y, Boussommier-Calleja A, et al., 2011. eNOS, a pressure-dependent regulator of intraocular pressure. Investigative Ophthalmology & Visual Science 52(13):9438-9444. doi:10.1167/iovs.11-7839
  5. Kang JH, Wiggs JL, Rosner BA, et al., 2011. Endothelial nitric oxide synthase gene variants and primary open-angle glaucoma: interactions with hypertension, alcohol intake, and cigarette smoking. Archives of Ophthalmology 129(6):773-780. doi:10.1001/archophthalmol.2011.118
  6. Patel PD, Chen YL, Kasetti RB, et al., 2021. Impaired TRPV4-eNOS signaling in trabecular meshwork elevates intraocular pressure in glaucoma. Proceedings of the National Academy of Sciences of the United States of America 118(16):e2022461118. doi:10.1073/pnas.2022461118
  7. Thorleifsson G, Walters GB, Hewitt AW, et al., 2010. Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma. Nature Genetics 42(10):906-909. doi:10.1038/ng.661
  8. Elliott MH, Ashpole NE, Gu X, et al., 2016. Caveolin-1 modulates intraocular pressure: implications for caveolae mechanoprotection in glaucoma. Scientific Reports 6:37127. doi:10.1038/srep37127
  9. Weinreb RN, Liebmann JM, Martin KR, et al., 2018. Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings. Journal of Glaucoma 27(1):7-15. doi:10.1097/IJG.0000000000000831
  10. Bosco A, Inman DM, Steele MR, et al., 2008. Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma. Investigative Ophthalmology & Visual Science 49(4):1437-1446. doi:10.1167/iovs.07-1337
  11. Howell GR, Soto I, Zhu X, et al., 2012. Radiation treatment inhibits monocyte entry into the optic nerve head and prevents neuronal damage in a mouse model of glaucoma. Journal of Clinical Investigation 122(4):1246-1261. doi:10.1172/JCI61135
  12. Diemler CA, MacLean M, Heuer SE, et al., 2024. Microglia depletion leads to increased susceptibility to ocular hypertension-dependent glaucoma. Frontiers in Aging Neuroscience 16:1396443. doi:10.3389/fnagi.2024.1396443
  13. Last JA, Pan T, Ding Y, et al., 2011. Elastic modulus determination of normal and glaucomatous human trabecular meshwork. Investigative Ophthalmology & Visual Science 52(5):2147-2152. doi:10.1167/iovs.10-6342
  14. Mavlyutov TA, Myrah JJ, Chauhan AK, et al., 2022. Fibronectin extra domain A (FN-EDA) causes glaucomatous trabecular meshwork, retina, and optic nerve damage in mice. Cell & Bioscience 12(1):72. doi:10.1186/s13578-022-00800-y
  15. Tripathi RC, Li J, Chan WF, et al., 1994. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Experimental Eye Research 59(6):723-727. doi:10.1006/exer.1994.1158
  16. Serle JB, Katz LJ, McLaurin E, et al., 2018. Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). American Journal of Ophthalmology 186:116-127. doi:10.1016/j.ajo.2017.11.019
  17. He Y, Leung KW, Zhang YH, et al., 2008. Mitochondrial complex I defect induces ROS release and degeneration in trabecular meshwork cells of POAG patients: protection by antioxidants. Investigative Ophthalmology & Visual Science 49(4):1447-1458. doi:10.1167/iovs.07-1361
  18. Tolman N, Li T, Balasubramanian R, et al., 2026. Single-cell profiling of trabecular meshwork identifies mitochondrial dysfunction in a glaucoma model that is protected by vitamin B3 treatment. eLife 14:RP107161. doi:10.7554/eLife.107161
  19. He Y, Leung KW, Zhuo YH, et al., 2009. Pro370Leu mutant myocilin impairs mitochondrial functions in human trabecular meshwork cells. Molecular Vision 15:815-825. PMID: 19390644
  20. Wang X, Lin B, Xu X, et al., 2026. Mitochondria transplantation reduces intraocular pressure by improving mitochondrial function and remodeling trabecular meshwork. Journal of Translational Medicine 24(1):331. doi:10.1186/s12967-026-07964-y
  21. Landmesser U, Dikalov S, Price SR, et al., 2003. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. Journal of Clinical Investigation 111(8):1201-1209. doi:10.1172/JCI14172
  22. Murugesan P, Zhang Y, Zhang M, et al., 2026. eNOS Uncoupling-ER Stress-Mitochondrial Dysfunction Axis in the Development of Pulmonary Hypertension. JACC: Basic to Translational Science 11(4):101512. doi:10.1016/j.jacbts.2026.101512
  23. Dikalova AE, Itani HA, Nazarewicz RR, et al., 2017. Sirt3 Impairment and SOD2 Hyperacetylation in Vascular Oxidative Stress and Hypertension. Circulation Research 121(5):564-574. doi:10.1161/CIRCRESAHA.117.310933
  24. Li F, Luo Y, Li X, et al., 2024. Association between metabolic syndrome and the risk of glaucoma: a meta-analysis of observational studies. Diabetology & Metabolic Syndrome 16(1):300. doi:10.1186/s13098-024-01532-4
  25. Sun Y, Sun Y, Wang M, et al., 2026. Chronic stress-induced steroids mediate mitochondrial fission and fibrosis in the trabecular meshwork via the MIEF1-MAOA complex. Free Radical Biology & Medicine 246:316-333. doi:10.1016/j.freeradbiomed.2026.01.037
  26. Wu H, Shui YB, Liu Y, et al., 2022. Trabecular Meshwork Mitochondrial Function and Oxidative Stress: Clues to Racial Disparities of Glaucoma. Ophthalmology Science 2(1):100107. doi:10.1016/j.xops.2021.100107
  27. Jung KI, Kim YC, Shin HJ, et al., 2025. Nationwide cohort study of primary open angle glaucoma risk and cardiovascular factors among in Korean glaucoma suspects. Scientific Reports 15(1):1952. doi:10.1038/s41598-025-85505-1
  28. Niu W, Qi Y, 2011. An updated meta-analysis of endothelial nitric oxide synthase gene: three well-characterized polymorphisms with hypertension. PLoS One 6(9):e24266. doi:10.1371/journal.pone.0024266
  29. Kazemi A, McLaren JW, Kopczynski CC, et al., 2018. The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans. Journal of Ocular Pharmacology and Therapeutics 34(5):380-386. doi:10.1089/jop.2017.0138
  30. Lin CW, Sherman B, Moore LA, et al., 2018. Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma. Journal of Ocular Pharmacology and Therapeutics 34(1-2):40-51. doi:10.1089/jop.2017.0023
  31. Izzotti A, Longobardi M, Cartiglia C, et al., 2011. Mitochondrial damage in the trabecular meshwork occurs only in primary open-angle glaucoma and in pseudoexfoliative glaucoma. PLoS One 6(1):e14567. doi:10.1371/journal.pone.0014567
  32. Kowa Co., Ltd., 2022. HYPADIL Kowa Ophthalmic Solution 0.25% (nipradilol), Japanese package insert, revised January 2022. Japanese prescribing information (JAPIC, via KEGG MEDICUS); approval no. 21800AMX10015. Package insert (KEGG/JAPIC)
  33. Hui F, Tang J, Williams PA, et al., 2020. Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: A crossover randomized clinical trial. Clinical & Experimental Ophthalmology 48(7):903-914. doi:10.1111/ceo.13818
  34. Chi W, Li F, Chen H, et al., 2014. Caspase-8 promotes NLRP1/NLRP3 inflammasome activation and IL-1β production in acute glaucoma. Proceedings of the National Academy of Sciences of the United States of America 111(30):11181-11186. doi:10.1073/pnas.1402819111
  35. Nakazawa T, Nakazawa C, Matsubara A, et al., 2006. Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. Journal of Neuroscience 26(49):12633-12641. doi:10.1523/JNEUROSCI.2801-06.2006
  36. Zhou R, Yazdi AS, Menu P, et al., 2011. A role for mitochondria in NLRP3 inflammasome activation. Nature 469(7329):221-225. doi:10.1038/nature09663
  37. Minhas PS, Liu L, Moon PK, et al., 2019. Macrophage de novo NAD(+) synthesis specifies immune function in aging and inflammation. Nature Immunology 20(1):50-63. doi:10.1038/s41590-018-0255-3
  38. Masumoto A, Hirooka Y, Shimokawa H, et al., 2001. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 38(6):1307-1310. doi:10.1161/hy1201.096541

Related: Sage — Eye · Sage — Nitric Oxide · Sage — Hypertension · Sage — Cardiology.

See the notice at the top of this page. Working hypothesis, not medical advice.